ViaScint data

The Research Triangle Park, N.C., company said data from two Phase III trials indicates that the imaging agent predicts with high accuracy which patients will have improvement in cardiac function following bypass surgery. Based on the outcomes, MRE plans to submit an NDA no later than the first quarter of 1996.

The trials evaluated residual myocardial viability in patients scheduled for bypass surgery who had coronary artery disease and left ventricular dysfunction. ...